脂质体伊立替康治疗HER2阴性乳腺癌脑转移:PHENOMENAL II期研究
PHENOMENAL是一项单臂、开放标签、多中心IIa期研究,纳入56例HER2阴性乳腺癌伴活动性或稳定性脑转移患者,其中91.1%基线时脑转移为进展性。脂质体伊立替康每14天静脉给药,主要终点进展性脑转移患者颅内客观缓解率(IC-ORR)达22.0%(95%CI 11.5-36.0,P<0.001),中位无进展生存期1.5个月,中位总生存期6.4个月。
要点
- 进展性脑转移患者颅内客观缓解率为22.0%(95%CI 11.5-36.0)
- 中位无进展生存期1.5个月,中位总生存期6.4个月
- 治疗相关≥3级不良事件发生率为14.3%,无治疗相关死亡
核心结论
- 脂质体伊立替康在HER2阴性乳腺癌脑转移患者中显示出颅内抗肿瘤活性,但总体疗效有限且长期结局仍差。
研究设计与样本
- PHENOMENAL(NCT03328884)为单臂、开放标签、多中心IIa期研究,在西班牙16个中心纳入56例女性患者。
- 纳入标准为HER2阴性乳腺癌伴活动性或稳定性脑转移,且既往接受过至少1线转移性疾病化疗(需≥1线紫杉类)。
- 脂质体伊立替康静脉给药,剂量为60 mg/m2(盐基)或50 mg/m2(游离碱),每14天一次,直至进展和/或不可耐受毒性。
- 主要终点为进展性脑转移患者的颅内客观缓解率(IC-ORR)。
主要发现
- 中位年龄52岁(范围32-83),51.8%为三阴性乳腺癌,91.1%基线时为进展性脑转移。
- 中位随访5.7个月(范围0.4-56.5),进展性脑转移患者IC-ORR为22.0%(95%CI 11.5-36.0,P<0.001)。
- 中位无进展生存期为1.5个月(95%CI 1.4-2.9),中位总生存期为6.4个月(95%CI 4.9-10.8)。
- 治疗中出现的不良事件发生率为96.4%,57.1%被认为与治疗相关,14.3%发生≥3级治疗相关事件。
- 仅1例患者发生严重治疗相关事件,无治疗相关死亡。
临床怎么用
- 脂质体伊立替康可作为HER2阴性乳腺癌脑转移患者的一种治疗选择,但需权衡有限的疗效与安全性。
局限性
- 单臂设计缺乏随机对照,样本量较小(56例),随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with breast cancer (BC) and brain metastases (BMs) have a poor prognosis, particularly those with human epidermal growth factor 2-negative (HER2[-]) BC, including hormone receptor-positive (HR[+]) and triple-negative breast cancer (TNBC). Liposomal irinotecan (nal-IRI) crosses the blood-brain barrier and enhances antitumor activity. METHODS: PHENOMENAL (NCT03328884) was a single-arm, open-label, multicenter phase 2a study in Spain. Eligible patients had HER2[-] BC with active or stable BMs and prior chemotherapy regimen for metastatic disease (≥1 taxane line required). Nal-IRI was administered intravenously at 60 mg/m2 (salt-base) or 50 mg/m2 (free-base) every 14 days until progression and/or unacceptable toxicity. The primary endpoint was intracranial objective response rate (IC-ORR) in patients with progressive BMs. Key secondary endpoints included ORR, clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Fifty-six women (median age 52 years; range, 32-83) were enrolled across 16 sites. Of these, 51.8 % had TNBC, and 91.1 % had progressive BMs at baseline. Median follow-up was 5.7 months (range, 0.4-56.5). The trial achieved its primary endpoint, with IC-ORR of 22.0 % (95 % CI, 11.5-36.0; p < 0.001) among patients with progressive BMs. Median PFS was 1.5 months (95 % CI, 1.4-2.9), while median OS reached 6.4 months (95 % CI, 4.9-10.8). Treatment-emergent adverse events (TEAEs) occurred in 96.4 % of patients; 57.1 % were considered treatment-related and 14.3 % experienced grade ≥ 3 treatment-related events. Only one patient had a serious treatment-related event, and no treatment-related deaths occurred. CONCLUSIONS: nal-IRI demonstrated IC activity in HER2[-] BC with BMs. While overall efficacy was limited and long-term outcomes remain poor, these results highlight the unmet need in this challenging population and support the importance of developing more treatment strategies.
引用
- Borrego MR, López-Bravo DP, Vila MM, et al. Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study. Eur J Cancer. 2025. PMID: 41371050. doi:10.1016/j.ejca.2025.116161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。